Answers are grounded in this paper and cite their sources.
Observational analysis revealed PPARα genotype links to chronic complications in type 2 diabetes, suggesting fenofibrate benefits in vascular health.
Peroxisome proliferator-activated receptor α (PPARα) regulates lipid metabolism, cardiac energy balance, vascular inflammation and cell differentiation. We examined whether a PPARα gene variant (rs6008845, C/T) is associated with risk of chronic complications and death, and with benefit of fenofibrate (a PPARα agonist) in adults with type 2 diabetes. The variant was genotyped in 8,159 participants in the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. During a median 5-year follow-up, 2,931 (35.9%) developed chronic complications, including 2,004 (24.6%) microvascular and 1,359 (16.7%) macrovascular events. The association with microvascular complications was non-linear, with the highest risk among T/T homozygotes (hazard ratio (HR) 1.15 (95% CI 1.01–1.31), p = 0.041 vs. C/C homozygotes). Each T allele was associated with higher risk of any vascular complication (HR 1.06 (1.00–1.12), p = 0.029), non-CVD-related mortality (HR 1.19 (1.01–1.41), p = 0.041), and cancer-related mortality (HR 1.19 (1.01–1.41), p = 0.041). A significant genotype-by-dyslipidemia interaction was observed for cancer-related mortality under the atherogenic dyslipidemia definition. Fenofibrate reduced microvascular, macrovascular, and composite vascular events (HR 0.79–0.87, all p < 0.02) with no evidence of treatment-by-genotype interaction. PPARα rs6008845 T allele was associated with a higher risk of microvascular complications and cancer death. Fenofibrate showed consistent vascular protection irrespective of PPARα genotype.
No takes yet. Share an insight, caveat, or question.
Januszewski et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: